Actuate Therapeutics Inc (ACTU) Sentiment Analysis
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
- ST sentiment gradeHow the market currently feels about this stock versus its peers
- —
- Overall ST grade
- C-
- ST Score
- 30.4
- Price change today
- —
- Strong buy
- —
- Buy
- —
- Hold
- —
- Sell
- —
- Strong sell
- —
- Bullish share0 bullish vs 0 bearish ratings
- —
Headline tone is a simple keyword scan of recent coverage, not a prediction.
ACTU stock: frequently asked questions
What is ACTU's ST Score?
Actuate Therapeutics Inc (ACTU) has an ST Score of 30.4 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ACTU a buy, hold, or sell?
Analysts rate ACTU a Buy, with a price target of $21.00 (+3287.1% vs the current price). Our ST Score grades it C- (30.4/100). The ST Score is a data-driven signal, not a recommendation.
What are ACTU's factor grades?
Valuation C, Profitability F, Financial Strength D-, Momentum D-, Growth C+, Forecast A.
What is ACTU's valuation grade?
Actuate Therapeutics Inc (ACTU) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ACTU's growth grade?
Actuate Therapeutics Inc (ACTU) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ACTU's profitability grade?
Actuate Therapeutics Inc (ACTU) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ACTU's financial strength grade?
Actuate Therapeutics Inc (ACTU) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ACTU?
The average analyst price target for Actuate Therapeutics Inc (ACTU) is $21.00 from 1 analysts, which is +3287.1% versus the recent price of $0.62.
What is ACTU's Piotroski score?
Actuate Therapeutics Inc (ACTU) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.